Research & Development

LAPROPHAN is the first Moroccan laboratory to dispose of an R&D center and to have been awarded five (5) national and international invention and innovation patent laws for:

Indomethacin calcium pentahydrate

Non-steroidal anti-inflammatory inhibitor of cyclooxygenase-2 (COX-2).

Molecular discovery and innovation, first in Africa and in the Middle East: The originality of this innovation gave rise to an international patent law.

Indomethacin calcium pentahydrate (DI-INDO®) is one of the most clinically efficient non-steroidal anti-inflammatory drugs, and one of the most powerful biological inhibitors of cyclo-oxygenase.

The mode of action of NSAIDs, including DI-INDO®, is primarily based on the inhibition of prostaglandin biosynthesis (partially responsible for inflammatory phenomena).

In addition, a study of the molecular biology comparing DI-INDO® with Indométacine showed that Indométacine Calcique Pentahydrate (DI-INDO®) inhibited COX2 in a similar way to Indométacine, which confirms the Identical anti-inflammatory efficacy revealed by clinical studies.

Concerning COX1, Indométacine Calcique Pentahydrate is less refined vis-à- vis the enzyme: IC50 is 6 times higher than that of Indométacine.

This report in favor of indometacin calcium pentahydrate (6x) found in the experimental conditions, explains the decrease in the digestive toxicity of the molecule, while retaining a powerful anti-inflammatory activity, supported by clinical studies.


The First antispasmodic in effervescent form,

Is a product resulting from Laprophan’s R&D.

The originality of the innovation has given rise to an international patent law.

The phloroglucinol is a musculotropic antispasmodic widely used for many years in the treatment of:

  • Symptomatic pain associated with functional disorders of the gastrointestinal tract and biliary tract,
  • Acute spasmodic and painful manifestations of the urinary tract (renal colic),
  • Symptomatic of painful spasmodic manifestations in gynecology.

Pharmacological studies have shown that NEOFORTAN® effervescent tablet has significantly higher anti-spasmodic activity than oral lyophilisate and is almost as effective as intramuscular injection.


The First anti-secretory effervescent Proton Pump Inhibitor.

Pursuing our research and development in order to provide patients and healthcare professionals with innovative pharmaceutical products, which meet all the international criteria of quality, safety and efficiency, LAPROPHAN has developed an original galenical formulation which endows omeprazole with protection against gastric acidity, a prerequisite to the bioavailability and consequently to the therapeutic activity of this active substance.

Actually, all available omeprazole drugs are in the form of capsules filled with gastroresistant microgranules.

The clinical study on humans showed that lxor® is an innovative drug which has a very good PPI activity combined with an instant buffer effect of gastric acidity, combining immediate and lasting relief.

This invention was subject of an international patent law and resulted in the inception of an innovative medicinal product having obtained marketing authorization.

IXOR® received the prestigious Exellence Award of the World Intellectual Property Organization (WIPO) in Geneva, as well as the National R&D Trophy awarded by the Moroccan Association for Research and Development.

Amoxicillin / Clavulanic Acid

First association between Amoxicillin / Clavulanic acid marketed in the form of effervescent tablets.

This galenical innovation is the result of the hard work of the research and development center within LAPROPHAN laboratories, the first center of its kind in the Moroccan national pharmaceutical industry.

Physicochemical stability studies carried out according to the International Conference of Harmonization (ICH) have shown:

  • Perfect stability throughout the validity period of the product.
  • Perfect stability throughout the treatment period.
  • Perfect stability up to a temperature of 30 ° C and a relative humidity of 65%.
The 5th Patent Law
Combination of phloroglucinol paracetamol, antispasmodic

The Innovation consists of a combination of an antispasmodic and an analgesic giving a synergy effect and an efficient action in case of spasms along with pains.